You are here: Industry Insights > GMP

News List

Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus Biotech Newswire
August 22, 2024
Touchlight announced the clinical supply of its proprietary dbDNA™ to the University of Nottingham for research and development of a next-generation DNA vaccine targeting the Zika virus.
WHO's Newest Updates in Pharmaceutical GMP Guidelines Saher Binte Haider
April 23, 2024
GMP is a fundamental concept in pharmaceutical manufacturing and distribution. Poor-quality medicinal products can lead to adverse effects, treatment failure, and even death. Implementing GMP assures that pharmaceutical products are produced with the high
The Future of GMP in the Pharmaceutical Industry Saher Binte Haider
March 21, 2024
The pharmaceutical industries are continuously evolving, which is why the future of GMP is on the brink of significant change.
cGMP regulations in pharmaceutical industry Muhammad Asim Niazi
June 14, 2023
Let’s look at some importance of GMP in pharma manufacturing and see how it benefits the pharma manufacturer.
InvestEU: EIB Agrees to a €18 Million Loan to Estonian Biotech Icosagen for Innovative R&D Technologies and New cGMP Production Facility PharmaSources
February 09, 2023
The Estonian biopharmaceutical innovator Icosagen AS has reached a €18 million financing agreement with the EIB to further strengthen its drug discovery, development and production services.
Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0. PharmaSources.com
April 07, 2022
Rokote Laboratories Finland Ltd., a vaccine development company focusing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.
GMP certification for Exothera further extends its viral vector manufacturing capacity PharmaSources.com
March 24, 2022
Exothera S.A., a CDMO specialized in the development and manufacture of viral vectors for vaccines and gene therapies, received Good Manufacturing Practices (GMP) certification from the Federal Agency for Medicines and Health Products...
Nanoform Signs GMP Manufacturing Program with TargTex contractpharma
February 04, 2022
Aims to enhance TargTex’s Glioblastoma multiforme drug candidate.
Successful Groundbreaking Ceremony for GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China prnasia
January 21, 2022
GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has announced 2022 manufacturing expansion plans to meet the increasing demand for commercial cGMP...